Stevanato Group S.p.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STVN research report →
Range $17.5 – $32
Price Chart
About the company
Stevanato Group S. p. A.
- CEO
- Franco Stevanato
- IPO
- 2021
- Employees
- 6,010
- HQ
- Piombino Dese, PD, IT
Get TickerSpark's AI analysis on STVN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $4.27B
- P/E
- 27.98
- Fwd P/E
- 26.33
- PEG
- -14.55
- P/S
- 3.14
- P/B
- 2.44
- EV/EBITDA
- 13.89
- Div Yield
- 0.40%
- Gross Margin
- 29.15%
- Op Margin
- 16.15%
- Net Margin
- 11.24%
- ROE
- 9.07%
- ROIC
- 6.22%
Latest fiscal year · YoY change
- Revenue
- $1.14B+3.2%
- Gross Profit
- $330.33M+9.3%
- Op Income
- $183.08M
- Net Income
- $134.28M+14.0%
- EPS
- $0.49+14.0%
- OCF Growth
- +76.4%
- FCF Growth
- +113.6%
- 52W High
- $24.01
- 52W Low
- $12.05
- 50D MA
- $18.75
- 200D MA
- $17.92
- Beta
- 0.80
- RSI (14)
- 45
- Avg Volume
- 649.01K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Stevanato delivered an in-line Q3 with 8% revenue growth and margin expansion, while warning that a one-customer GLP-1 slowdown will likely temper 2027 growth before the business normalizes later.· November 3, 2026
- Q3 revenue rose 8% to EUR 326.1 million, with adjusted EBITDA up 14% to EUR 88.8 million and adjusted EBITDA margin at 27.2%.
- BDS remained the engine: segment revenue was EUR 294 million, up 10% reported and 11% organically, while engineering revenue fell 12% to EUR 32 million.
- Management said the 2027 GLP-1 headwind is tied to one customer and mostly to Nexa syringes, but believes most of the volume can be backfilled.
- Full-year 2026 guidance was reiterated for revenue, adjusted EBITDA, and adjusted EPS, though engineering revenue and CapEx assumptions were updated.
- Fishers reached gross profit breakeven, Latina and other high-value capacity additions are progressing, and the company expects positive free cash flow next year.
Third-quarter 2026 revenue increased 8% to EUR 326.1 million, both reported and organically. Gross profit margin was 29.1%, down 10 basis points year over year. Operating profit margin rose 110 basis points to 18.5%, adjusted operating profit margin was 19.4%, net profit increased 16% to EUR 41.8 million, diluted EPS was EUR 0.15, adjusted net profit was EUR 44 million, adjusted diluted EPS was EUR 0.16, and adjusted EBITDA rose 14% to EUR 88.8 million with a 27.2% margin. For full-year 2026, management reiterated revenue guidance of EUR 1.26 billion to EUR 1.28 billion, adjusted EBITDA of EUR 335 million to EUR 345.2 million, and adjusted diluted EPS of EUR 0.60 to EUR 0.62. It now expects engineering revenue of EUR 124 million to EUR 134 million and CapEx of EUR 230 million to EUR 240 million, or EUR 215 million to EUR 225 million net of customer contribution.
Franco Stevanato said the quarter was in line with expectations and emphasized that demand in injectable biologics remains structurally strong. He framed the main issue for 2027 as a temporary moderation from one GLP-1 customer, concentrated in Nexa syringes, but said the company has already taken action to backfill most of that volume through non-GLP biologics, Alba, cartridges, and delivery-device programs. His tone was confident and medium-term focused, repeatedly stressing that the long-term growth trajectory remains intact and that the business should normalize again in 2028.
Marco Dal Lago quantified the quarter and the balance sheet: cash and cash equivalents were EUR 114.9 million, net debt was EUR 353.7 million, operating cash flow was EUR 57.6 million, CapEx was EUR 44.8 million, and free cash flow was EUR 21.7 million. He said gross margin was pressured by higher utility costs, higher depreciation, and lower engineering gross profit, partially offset by better mix and improvement in Latina and Fishers. He also said the company has adequate liquidity and updated 2026 CapEx up to EUR 230 million to EUR 240 million, while reiterating that stronger BDS growth should offset the weaker engineering outlook.
Analysts focused on the size and cause of the GLP-1 slowdown, whether it reflected lost share or inventory issues, and whether the company could truly backfill the volume. Management said the headwind is tied to one customer and mainly to syringes, not a broader portfolio issue, and stressed contractual protections such as take-or-pay, minimum quantities, and capacity reservation. Questions also addressed engineering order delays and Fishers profitability; management said engineering is operationally improved but slower to convert pipeline into orders, and that Fishers is on track to keep ramping toward full capacity by the end of 2028.
The company is seeing strong demand in non-GLP biologics, with management citing 13% year-to-date growth and broad traction across Alba, EZ-fill cartridges, and delivery devices. Fishers reached breakeven at the gross profit level, Latina is adding high-value capacity, and management expects growth to reaccelerate after the temporary 2027 GLP-1 headwind rolls off.
Management acknowledged that 2027 growth will likely moderate because of lower GLP-1 volumes from one customer, and that some revenue backfill will take time because of validation and customer timing. Engineering remains a weak spot, with delayed order conversions and order timing pressure from a key customer, and gross margins also face utility-cost pressure in Europe.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 100.0%
- Shares Outstanding
- 273.13M
- Float Shares
- 273.13M
of shares held by institutions
127 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Neuberger Berman Group LLC | 5.61M | ▼ 17.24K |
| Conestoga Capital Advisors, LLC | 5.60M | ▼ 1.41M |
| Timessquare Capital Management, LLC | 3.25M | ▼ 221.74K |
| Van Berkom & Associates Inc. | 2.86M | ▼ 110.90K |
| Artisan Partners Limited Partnership | 2.57M | ▼ 35.71K |
| Bamco Inc | 2.49M | ▼ 5.57K |
| American Century Companies Inc | 1.65M | ▲ 1.65M |
| Credit Agricole S A | 1.30M | 0 |
| Wellington Management Group Llp | 1.25M | ▲ 1.25M |
| Morgan Stanley | 1.12M | ▼ 188.40K |
| Ranger Investment Management, L.P. | 948.35K | ▼ 238.02K |
| Royce & Associates LP | 915.02K | ▼ 1.34K |
Held by 19 ETFs
Biggest fund positions in STVN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 9, 26 | FEDERICI WILLIAM J | buy | 20,000 |
| Nov 6, 26 | MOREL DONALD E JR | buy | 25,000 |
| Sep 28, 26 | Stocchi Mauro | sell | 13,649 |
| Aug 7, 26 | Santel Luciano | sell | 2,023 |
| Aug 7, 26 | Dal Lago Marco | sell | 4,209 |
| Aug 7, 26 | Magistretti Elisabetta | sell | 2,045 |
| Jun 12, 26 | Balachandran Madhavan | other | 4,975 |
| Jun 15, 26 | Balachandran Madhavan | sell | 1,493 |
| Jun 12, 26 | Dal Lago Marco | other | 7,997 |
| Jun 12, 26 | Dal Lago Marco | other | 2,356 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STVN coverage
Recent articles, reports, and earnings notes.
No research on STVN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STVN report →Stevanato Group to Participate in Upcoming Investor Conferences
gurufocus.com · Nov 16
Stevanato Group to Participate in Upcoming Investor Conferences
businesswire.com · Nov 16
STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law
gurufocus.com · Nov 7
STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law
businesswire.com · Nov 7
STVN INVESTOR ALERT: Investigation of Stevanato Group S.p.A. Announced by Holzer & Holzer, LLC
globenewswire.com · Nov 4
Lost Money on Stevanato Group S.p.A. Shares? The Law Offices of Frank R.
businesswire.com · Nov 4
Lost Money on Stevanato Group S.p.A. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 28.57% Share Price Drop
businesswire.com · Nov 4
Did You Lose Money on Stevanato Group S.p.A. Stock? The Law Offices of Howard G.
businesswire.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.